ProteinQure

ProteinQure is a biotechnology company pioneering computational peptide therapeutics. They are developing a drug discovery platform, ProteinStudio™, to design therapeutic peptides using machine learning, structural biology, and atomic-level simulations, enabling tissue-specific delivery and access to novel target classes. Their lead candidate, PQ203, is a first-in-class peptide-drug conjugate designed to target triple-negative breast cancer.

Funding Round: Series A

Funding Amount: $11M

Date: 28-May-2025

Investors: Tom Williams, Heron Rock Fund, Golden Ventures, Kensington Capital, and select returning investors

Markets: Biotech, Oncology, Neurology, Nephrology, Drug Discovery

HQ: Toronto, Ontario, Canada

Founded: 2017

Website: https://www.proteinqure.com/

LinkedIn: https://www.linkedin.com/company/proteinqure

Twitter: https://twitter.com/proteinqure

Instagram:

Facebook: https://www.facebook.com/proteinqure